Lynette M Sholl1, Dara L Aisner2, Marileila Varella-Garcia3, Lynne D Berry4, Dora Dias-Santagata5, Ignacio I Wistuba6, Heidi Chen4, Junya Fujimoto6, Kelly Kugler7, Wilbur A Franklin2, A John Iafrate5, Marc Ladanyi8, Mark G Kris8, Bruce E Johnson9, Paul A Bunn10, John D Minna11, David J Kwiatkowski12. 1. Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. 2. Department of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado. 3. Department of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado; Division of Medical Oncology, Department of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado. 4. Vanderbilt-Ingram Cancer Center, Nashville, Tennessee. 5. Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 6. Department of Translational Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas. 7. Division of Medical Oncology, Department of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado. 8. Memorial Sloan Kettering Cancer Center, New York, New York. 9. Department of Medicine, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts. 10. Division of Medical Oncology, Department of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado; Lung Cancer Mutation Consortium, University of Colorado Cancer Center, Aurora, Colorado. 11. University of Texas Southwestern, Dallas, Texas. 12. Department of Medicine, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address: dk@rics.bwh.harvard.edu.
Abstract
INTRODUCTION: Molecular genetic analyses of lung adenocarcinoma have recently become standard of care for treatment selection. The Lung Cancer Mutation Consortium was formed to enable collaborative multi-institutional analyses of 10 potential oncogenic driver mutations. Technical aspects of testing and clinicopathologic correlations are presented. METHODS: Mutation testing in at least one of the eight genes (epidermal growth factor receptor [EGFR], KRAS, ERBB2, AKT1, BRAF, MEK1, NRAS, and PIK3CA) using SNaPshot, mass spectrometry, Sanger sequencing+/- peptide nucleic acid and/or sizing assays, along with anaplastic lymphoma kinase (ALK) and/or MET fluorescence in situ hybridization, were performed in six labs on 1007 patients from 14 institutions. RESULTS: In all, 1007 specimens had mutation analysis performed, and 733 specimens had all 10 genes analyzed. Mutation identification rates did not vary by analytic method. Biopsy and cytology specimens were inadequate for testing in 26% and 35% of cases compared with 5% of surgical specimens. Among the 1007 cases with mutation analysis performed, EGFR, KRAS, ALK, and ERBB2 alterations were detected in 22%, 25%, 8.5%, and 2.4% of cases, respectively. EGFR mutations were highly associated with female sex, Asian race, and never-smoking status; and less strongly associated with stage IV disease, presence of bone metastases, and absence of adrenal metastases. ALK rearrangements were strongly associated with never-smoking status and more weakly associated with presence of liver metastases. ERBB2 mutations were strongly associated with Asian race and never-smoking status. Two mutations were seen in 2.7% of samples, all but one of which involved one or more of PIK3CA, ALK, or MET. CONCLUSION: Multi-institutional molecular analysis across multiple platforms, sample types, and institutions can yield consistent results and novel clinicopathological observations.
INTRODUCTION: Molecular genetic analyses of lung adenocarcinoma have recently become standard of care for treatment selection. The Lung Cancer Mutation Consortium was formed to enable collaborative multi-institutional analyses of 10 potential oncogenic driver mutations. Technical aspects of testing and clinicopathologic correlations are presented. METHODS: Mutation testing in at least one of the eight genes (epidermal growth factor receptor [EGFR], KRAS, ERBB2, AKT1, BRAF, MEK1, NRAS, and PIK3CA) using SNaPshot, mass spectrometry, Sanger sequencing+/- peptide nucleic acid and/or sizing assays, along with anaplastic lymphoma kinase (ALK) and/or MET fluorescence in situ hybridization, were performed in six labs on 1007 patients from 14 institutions. RESULTS: In all, 1007 specimens had mutation analysis performed, and 733 specimens had all 10 genes analyzed. Mutation identification rates did not vary by analytic method. Biopsy and cytology specimens were inadequate for testing in 26% and 35% of cases compared with 5% of surgical specimens. Among the 1007 cases with mutation analysis performed, EGFR, KRAS, ALK, and ERBB2 alterations were detected in 22%, 25%, 8.5%, and 2.4% of cases, respectively. EGFR mutations were highly associated with female sex, Asian race, and never-smoking status; and less strongly associated with stage IV disease, presence of bone metastases, and absence of adrenal metastases. ALK rearrangements were strongly associated with never-smoking status and more weakly associated with presence of liver metastases. ERBB2 mutations were strongly associated with Asian race and never-smoking status. Two mutations were seen in 2.7% of samples, all but one of which involved one or more of PIK3CA, ALK, or MET. CONCLUSION: Multi-institutional molecular analysis across multiple platforms, sample types, and institutions can yield consistent results and novel clinicopathological observations.
Authors: Hollis Viray; Kevin Li; Thomas A Long; Patricia Vasalos; Julia A Bridge; Lawrence J Jennings; Kevin C Halling; Meera Hameed; David L Rimm Journal: Arch Pathol Lab Med Date: 2013-11 Impact factor: 5.534
Authors: Mark G Kris; Bruce E Johnson; Lynne D Berry; David J Kwiatkowski; A John Iafrate; Ignacio I Wistuba; Marileila Varella-Garcia; Wilbur A Franklin; Samuel L Aronson; Pei-Fang Su; Yu Shyr; D Ross Camidge; Lecia V Sequist; Bonnie S Glisson; Fadlo R Khuri; Edward B Garon; William Pao; Charles Rudin; Joan Schiller; Eric B Haura; Mark Socinski; Keisuke Shirai; Heidi Chen; Giuseppe Giaccone; Marc Ladanyi; Kelly Kugler; John D Minna; Paul A Bunn Journal: JAMA Date: 2014-05-21 Impact factor: 56.272
Authors: Maria E Arcila; Jamie E Chaft; Khedoudja Nafa; Sinchita Roy-Chowdhuri; Christopher Lau; Michael Zaidinski; Paul K Paik; Maureen F Zakowski; Mark G Kris; Marc Ladanyi Journal: Clin Cancer Res Date: 2012-07-03 Impact factor: 12.531
Authors: Marcel Wiesweg; Saskia Ting; Henning Reis; Karl Worm; Stefan Kasper; Mitra Tewes; Anja Welt; Heike Richly; Johannes Meiler; Sebastian Bauer; Jörg Hense; Thomas C Gauler; Jens Köhler; Wilfried E Eberhardt; Kaid Darwiche; Lutz Freitag; Georgios Stamatis; Frank Breitenbücher; Jeremias Wohlschlaeger; Dirk Theegarten; Cordula Derks; Diana Cortes-Incio; Gabriele Linden; Silke Skottky; Peter Lütkes; Alexander Dechêne; Andreas Paul; Peter Markus; Kurt W Schmid; Martin Schuler Journal: Eur J Cancer Date: 2013-07-19 Impact factor: 9.162
Authors: Jeffrey A Engelman; Kreshnik Zejnullahu; Tetsuya Mitsudomi; Youngchul Song; Courtney Hyland; Joon Oh Park; Neal Lindeman; Christopher-Michael Gale; Xiaojun Zhao; James Christensen; Takayuki Kosaka; Alison J Holmes; Andrew M Rogers; Federico Cappuzzo; Tony Mok; Charles Lee; Bruce E Johnson; Lewis C Cantley; Pasi A Jänne Journal: Science Date: 2007-04-26 Impact factor: 47.728
Authors: Garrett M Frampton; Alex Fichtenholtz; Geoff A Otto; Kai Wang; Sean R Downing; Jie He; Michael Schnall-Levin; Jared White; Eric M Sanford; Peter An; James Sun; Frank Juhn; Kristina Brennan; Kiel Iwanik; Ashley Maillet; Jamie Buell; Emily White; Mandy Zhao; Sohail Balasubramanian; Selmira Terzic; Tina Richards; Vera Banning; Lazaro Garcia; Kristen Mahoney; Zac Zwirko; Amy Donahue; Himisha Beltran; Juan Miguel Mosquera; Mark A Rubin; Snjezana Dogan; Cyrus V Hedvat; Michael F Berger; Lajos Pusztai; Matthias Lechner; Chris Boshoff; Mirna Jarosz; Christine Vietz; Alex Parker; Vincent A Miller; Jeffrey S Ross; John Curran; Maureen T Cronin; Philip J Stephens; Doron Lipson; Roman Yelensky Journal: Nat Biotechnol Date: 2013-10-20 Impact factor: 54.908
Authors: Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi Journal: J Mol Diagn Date: 2013-04-04 Impact factor: 5.568
Authors: Richard J Cassidy; Xinyan Zhang; Jeffrey M Switchenko; Pretesh R Patel; Joseph W Shelton; Sibo Tian; Ronica H Nanda; Conor E Steuer; Rathi N Pillai; Taofeek K Owonikoko; Suresh S Ramalingam; Felix G Fernandez; Seth D Force; Theresa W Gillespie; Walter J Curran; Kristin A Higgins Journal: Cancer Date: 2018-01-08 Impact factor: 6.860
Authors: Robin Guo; Lynne D Berry; Dara L Aisner; Jamie Sheren; Theresa Boyle; Paul A Bunn; Bruce E Johnson; David J Kwiatkowski; Alexander Drilon; Lynette M Sholl; Mark G Kris Journal: J Thorac Oncol Date: 2019-06-20 Impact factor: 15.609
Authors: Adrian G Sacher; Cloud Paweletz; Suzanne E Dahlberg; Ryan S Alden; Allison O'Connell; Nora Feeney; Stacy L Mach; Pasi A Jänne; Geoffrey R Oxnard Journal: JAMA Oncol Date: 2016-08-01 Impact factor: 31.777
Authors: Cheri A Pasch; Peter F Favreau; Alexander E Yueh; Christopher P Babiarz; Amani A Gillette; Joe T Sharick; Mohammad Rezaul Karim; Kwangok P Nickel; Alyssa K DeZeeuw; Carley M Sprackling; Philip B Emmerich; Rebecca A DeStefanis; Rosabella T Pitera; Susan N Payne; Demetra P Korkos; Linda Clipson; Christine M Walsh; Devon Miller; Evie H Carchman; Mark E Burkard; Kayla K Lemmon; Kristina A Matkowskyj; Michael A Newton; Irene M Ong; Michael F Bassetti; Randall J Kimple; Melissa C Skala; Dustin A Deming Journal: Clin Cancer Res Date: 2019-06-07 Impact factor: 12.531
Authors: James H Suh; Alexa B Schrock; Adrienne Johnson; Doron Lipson; Laurie M Gay; Shakti Ramkissoon; Jo-Anne Vergilio; Julia A Elvin; Abdur Shakir; Peter Ruehlman; Karen L Reckamp; Sai-Hong Ignatius Ou; Jeffrey S Ross; Philip J Stephens; Vincent A Miller; Siraj M Ali Journal: Oncologist Date: 2018-03-14
Authors: Etay Ziv; Joseph P Erinjeri; Hooman Yarmohammadi; F Edward Boas; Elena N Petre; Song Gao; Waleed Shady; Constantinos T Sofocleous; David R Jones; Charles M Rudin; Stephen B Solomon Journal: Radiology Date: 2016-07-19 Impact factor: 11.105